Caliway Biopharmaceuticals Co Ltd 6919
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 6919 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 614.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Caliway Biopharmaceuticals Co Ltd is specialized in the development of new drugs for medical aesthetic and inflammatory diseases. Its leading candidate, CBL-514, is a new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 41
- Website
- https://www.caliway.com.tw
Comparables
Valuation
|
Metric
|
6919
|
6535
|
6696
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.21 | 20.26 | 3.42 |
Price/Sales | 614.19 | 489.36 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
6919
|
6535
|
6696
|
|---|---|---|---|
Quick Ratio | 50.48 | 3.98 | 13.67 |
Current Ratio | 50.81 | 4.75 | 14.10 |
Interest Coverage | −1,014.81 | −5,543.09 | −647.17 |
Quick Ratio
6919
6535
6696
Profitability
|
Metric
|
6919
|
6535
|
6696
|
|---|---|---|---|
Return on Assets (Normalized) | −23.10% | −18.03% | −37.22% |
Return on Equity (Normalized) | −24.00% | −20.75% | −61.30% |
Return on Invested Capital (Normalized) | −24.56% | −20.75% | −39.00% |
Return on Assets
6919
6535
6696
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mktjcjfnqx | Qzvnh | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kkymktyc | Fmvsk | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jftspxzt | Wltcrst | $97.3 Bil | |
MRNA
| Moderna Inc | Cwbtfmrq | Rwtv | $41.3 Bil | |
ARGX
| argenx SE ADR | Lpfdmpbt | Kryt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zrplwgnv | Krqps | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rblzpfdb | Khstq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Njznjsnyq | Dlhjhjf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kvzkkqdvz | Vnvqfk | $12.6 Bil | |
INCY
| Incyte Corp | Pnrfhmgvn | Trjgkks | $11.8 Bil |